v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The operating financial results of the Company’s R&D segment for the three months ended March 31, 2025 and 2024 are as follows (in thousands):
Three Months Ended March 31,
20252024
Revenue$858 $— 
Less: Significant segment expenses
Personnel-related expenses5,187 4,681 
Clinical and preclinical expenses4,479 4,374 
Facilities-related and overhead1,976 1,908 
Professional and consulting fees1,601 1,521 
Corporate expenses581 241 
Travel and entertainment134 150 
Plus: Other segment income667 423 
Segment net loss$(12,433)$(12,452)